全文获取类型
收费全文 | 254篇 |
免费 | 5篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 9篇 |
基础医学 | 32篇 |
口腔科学 | 30篇 |
临床医学 | 12篇 |
内科学 | 47篇 |
皮肤病学 | 5篇 |
神经病学 | 17篇 |
特种医学 | 3篇 |
外科学 | 17篇 |
预防医学 | 25篇 |
眼科学 | 6篇 |
药学 | 39篇 |
中国医学 | 11篇 |
肿瘤学 | 5篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 1篇 |
2020年 | 4篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 1篇 |
2016年 | 3篇 |
2015年 | 8篇 |
2014年 | 7篇 |
2013年 | 16篇 |
2012年 | 23篇 |
2011年 | 15篇 |
2010年 | 14篇 |
2009年 | 15篇 |
2008年 | 14篇 |
2007年 | 21篇 |
2006年 | 23篇 |
2005年 | 20篇 |
2004年 | 16篇 |
2003年 | 22篇 |
2002年 | 14篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1972年 | 1篇 |
1960年 | 1篇 |
1956年 | 1篇 |
排序方式: 共有260条查询结果,搜索用时 15 毫秒
111.
Sukontason K Unpunyo P Sukontason KL Piangjai S 《Scandinavian journal of infectious diseases》2005,37(5):388-390
Haplorchis taichui is the minute intestinal fluke which parasitizes the small intestine of humans and other mammals. We present the pathology in the small intestine of 3 human cases caused by H. taichui. Microscopic examination revealed mucosal ulceration, mucosal and submucosal haemorrhages, fusion and shortening villi, chronic inflammation, and fibrosis of the submucosa. This finding clearly indicated H. taichui as pathogenic; thus prevention of infection and treatment should be paramount. 相似文献
112.
113.
Rukachaisirikul V Saelim S Karnsomchoke P Phongpaichit S 《Journal of natural products》2005,68(8):1222-1225
Five new triterpenes, one 17,14-friedolanostane (garcihombronane F, 1), three 17,13-friedolanostanes (garcihombronanes G-I, 2-4), and one lanostane (garcihombronane J, 5), were isolated from the leaves of Garcinia hombroniana together with nine known compounds including five triterpenes, two ionone-derived glycosides, and two flavonoid glucosides. Their structures were identified by analysis of spectroscopic data and comparison of the NMR data with those previously reported. 相似文献
114.
Haponsaph R Darden JM Chantakulkij S Sannoi N de Souza MS Brown AE Birx DL Polonis VR Pattanapanyasat K 《Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand》2004,22(1):39-48
To determine whether CD8+ T lymphocytes from Thai donor cells are susceptible to HIV-1 infection, undepleted peripheral blood mononuclear cells (PBMC) and CD8-enriched PBMC were infected with HIV-1 Thai subtype B and CRF01_AE (E) primary isolates. Virus kinetics in HIV-1 infection of CD4+ and CD8+ T lymphocytes peaked at day 7 or 10 post infection (pi); the TCID50 used for cell infection was proportional to the level of p24 production in the cultures. We also found that the level of p24 antigen in the supernatants of infected undepleted PBMC was significantly higher than that of infected CD8-enriched PBMC. Interestingly, both single positive T lymphocytes (CD4+ and CD8+ T lymphocytes) as well as double positive CD4+/CD8+ T lymphocytes were infected with HIV-1. The double positive T lymphocytes in PBMC were found only in the presence of both CD4+ and CD8+ T lymphocytes. The majority of p24+/CD4-/CD8- T lymphocytes were HIV-1 infected CD4 down-modulated PBMC. This report provides direct evidence that single positive CD8+ T lymphocytes and double positive CD4+/ CD8+ T lymphocytes from Thai donors can be infected with HIV-1 subtypes B and E in vitro. 相似文献
115.
116.
117.
118.
Kongkiat KULKANTRAKORN Panas TANYAKITPISAL Somchai TOWANABUT Charungthai DEJTHEVAPORN Poonsri RANGSEEKAJEE Sunsanee PONGPAKDEE Somsak LAPTIKULTHAM Kritsada RODPRASERT Suwanna SETTHAWATCHARAWANICH Bandit THINKHAMROP 《Psychogeriatrics》2013,13(1):1-8
Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer's disease (AD) and dementia associated with Parkinson's disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivastigmine patch in treatment of mild to moderate AD in clinical practice in Thailand. Methods: A multicentre, hospital‐based, prospective observational study was conducted in nine hospitals across Thailand. Patients with probable mild to moderate AD who received the rivastigmine patch were enrolled. Data were collected data at baseline, weeks 4–8 and after week16. Results: A total of 116 AD patients were screened, and three were excluded. Of 113 patients, 62.8% were women with a mean age of 73.3 ± 9.2 years; 79.7% were newly diagnosed. One‐third of all patients had been using antipsychotic or antidepressant medication. Common comorbidities were hypertension and dyslipidemia. The Thai Mental State Examination score significantly increased from 18.6 to 20.3 (weeks 4–8) and 20.4 (week 16+) (P < 0.001). Scores based on physicians’ (Clinical Global Impression) and caregivers’ (Patients’ Caregiver Global Impression of Change) impressions of improvement suggested minimal improvement. Because of adverse events, seven patients's dosages were reduced 10 cm2 to 5 cm2 or from 5 cm2 to nothing. Itching was the most common adverse symptom. Conclusions: During the first 16 weeks after initiation of rivastigmine patch therapy, patients with probable mild to moderate AD had statistically significant improvement in cognitive function, but clinically marginal benefit. Rivastigmine was safe and well tolerated. 相似文献
119.
120.
Kongkiat Kulkantrakorn Kittisak Sawanyawisuth Somsak Tiamkao 《Neurological sciences》2010,31(5):571-573
We studied factors associated with quality of life (QOL) among myasthenia gravis (MG) patients in two university hospitals
in Thailand: Thammasat University (TU) and Khon Kaen University (KKU). Consecutive MG patients from an outpatient neurology
clinic of both sites were enrolled and their clinical variables and QOL by the Short-Form 36 questionnaire were assessed.
There were 31 and 40 subjects enrolled at TU and KKU, respectively. The mean values of the SF-36 score in seven dimensions
were higher at the TU site. The significant factors between both sites were mean age, and numbers of participants with myasthenic
symptoms and steroid treatment. The frequency of MG symptoms was the only factor associated with the SF-36 score (correlation
coefficient −0.66, p value < 0.01). In conclusion, the frequency of MG symptoms might be the main factor that lowers QOL in MG patients in both
physical and mental aspects. 相似文献